NCT04375267

177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours

Phase I Trial With 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Vastra Gotaland Region · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase I study of 177Lu-DOTA-TATE in combination with the PARP-inhibitor olaparib for treatment of patients with somatostatin receptor positive tumours detected by 68Ga-DOTA-TATE/TOC PET. The combination of a PARP inhibitor that will specifically target the repair mechanism, with ionising radiation causing SSB's might overcome the repair dependent survival of the tumour cells, making them more sensitive to β-emission and increase the probability of tumour cell death.

Conditions

• Clinical Trial, Phase I
• Neuroendocrine Tumors
• Thymoma
• Mesothelioma

Interventions

Type	Name	Description
DRUG	177Lu-DOTA-TATE + olaparib	177Lu-DOTA-TATE in four cycles in combination with escalated doses of olaparib

Timeline

• Start date: 2020-04-23
• Primary completion: 2024-06-30
• Completion: 2024-06-30
• First posted: 2020-05-05
• Last updated: 2026-04-14

Locations

1 site across 1 country: Sweden